PMID- 37232810
OWN - NLM
STAT- MEDLINE
DCOM- 20230529
LR  - 20230602
IS  - 1718-7729 (Electronic)
IS  - 1198-0052 (Print)
IS  - 1198-0052 (Linking)
VI  - 30
IP  - 5
DP  - 2023 Apr 30
TI  - Estimating the Burden of Illness of Relapsed Follicular Lymphoma and Marginal 
      Zone Lymphoma in Ontario, Canada.
PG  - 4663-4676
LID - 10.3390/curroncol30050352 [doi]
AB  - BACKGROUND: Many patients with advanced follicular lymphoma (FL) and marginal 
      zone lymphoma (MZL) relapse after first-line chemotherapy. OBJECTIVE: To examine 
      healthcare resource utilization (HCRU) and cost, treatment patterns, progression, 
      and survival of patients with FL and MZL who relapse after first-line treatment, 
      in Ontario, Canada. METHODS: A retrospective, administrative data study 
      identified patients with relapsed FL and MZL (1 January 2005-31 December 2018). 
      Patients were followed for up to three years post relapse to assess HCRU, 
      healthcare costs, time to next treatment (TTNT), and overall survival (OS), 
      stratified by first- and second-line treatment. RESULTS: The study identified 285 
      FL and 68 MZL cases who relapsed after first-line treatment. Average duration of 
      first-line treatment was 12.4 and 13.4 months for FL and MZL patients, 
      respectively. Drug (35.9%) and cancer clinic costs (28.1%) were major 
      contributors to higher costs in year 1. Three-year OS was 83.9% after FL and 
      74.2% after MZL relapse. No statistically significant differences were observed 
      in TTNT and OS between patients with FL who received R-CHOP/R-CVP/BR in the first 
      line only versus both the first- and second- line. A total of 31% of FL and 34% 
      of MZL patients progressed to third-line treatment within three years of initial 
      relapse. CONCLUSION: Relapsing and remitting nature of FL and MZL in a subset of 
      patients results in substantial burden to patients and the healthcare system.
FAU - Kuruvilla, John
AU  - Kuruvilla J
AD  - Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 
      610 University Avenue, Toronto, ON M5G 2C1, Canada.
AD  - Department of Medicine, University of Toronto, Toronto, ON M5S 3H7, Canada.
FAU - Ewara, Emmanuel M
AU  - Ewara EM
AD  - Market Access, Janssen Canada Inc., 19 Green Belt Drive, North York, ON M3C 1L9, 
      Canada.
FAU - Elia-Pacitti, Julia
AU  - Elia-Pacitti J
AD  - Medical Affairs, Janssen Canada Inc., 19 Green Belt Drive, North York, ON M3C 
      1L9, Canada.
FAU - Ng, Ryan
AU  - Ng R
AD  - Real World Solutions, IQVIA, 16720 Rte Transcanadienne, Kirkland, QC H9H 5M3, 
      Canada.
FAU - Eberg, Maria
AU  - Eberg M
AD  - Real World Solutions, IQVIA, 16720 Rte Transcanadienne, Kirkland, QC H9H 5M3, 
      Canada.
FAU - Kukaswadia, Atif
AU  - Kukaswadia A
AD  - Real World Solutions, IQVIA, 300-6700 Century Avenue, Mississauga, ON L5N 6A4, 
      Canada.
FAU - Sharma, Arushi
AU  - Sharma A
AD  - Real World Solutions, IQVIA, 535 Legget Drive, Tower C, 7th Floor, Ottawa, ON K2K 
      3B8, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230430
PL  - Switzerland
TA  - Curr Oncol
JT  - Current oncology (Toronto, Ont.)
JID - 9502503
SB  - IM
MH  - Humans
MH  - *Lymphoma, Follicular/drug therapy/epidemiology
MH  - Ontario/epidemiology
MH  - Retrospective Studies
MH  - Neoplasm Recurrence, Local/epidemiology
MH  - *Lymphoma, B-Cell, Marginal Zone/drug therapy/epidemiology/pathology
MH  - Cost of Illness
PMC - PMC10216939
OTO - NOTNLM
OT  - burden of illness
OT  - costs
OT  - epidemiology
OT  - follicular lymphoma
OT  - marginal zone lymphoma
COIS- Emmanuel Ewara is an employee of Janssen Inc. and a stockholder of Johnson & 
      Johnson. Julia Pacitti is an employee of Janssen Inc. and a stockholder of 
      Johnson & Johnson. Ryan Ng, Maria Eberg, Atif Kukaswadia, and Arushi Sharma are 
      employees of IQVIA Solutions Canada Inc. IQVIA is a contract research 
      organization which received consulting fees from Janssen Inc.
EDAT- 2023/05/26 13:09
MHDA- 2023/05/29 06:42
PMCR- 2023/04/30
CRDT- 2023/05/26 09:34
PHST- 2023/03/14 00:00 [received]
PHST- 2023/04/21 00:00 [revised]
PHST- 2023/04/24 00:00 [accepted]
PHST- 2023/05/29 06:42 [medline]
PHST- 2023/05/26 13:09 [pubmed]
PHST- 2023/05/26 09:34 [entrez]
PHST- 2023/04/30 00:00 [pmc-release]
AID - curroncol30050352 [pii]
AID - curroncol-30-00352 [pii]
AID - 10.3390/curroncol30050352 [doi]
PST - epublish
SO  - Curr Oncol. 2023 Apr 30;30(5):4663-4676. doi: 10.3390/curroncol30050352.